Skip to main content
. Author manuscript; available in PMC: 2012 Jul 3.
Published in final edited form as: Int J Neuropsychopharmacol. 2011 Jul;14(6):721–734. doi: 10.1017/S1461145710001616

Fig. 4.

Fig. 4

GABA-related transcript expression levels after removal of subject pairs with potential confounding factors. The mean (hash mark) and individual (circle) 2–dCt relative expression values are plotted by diagnostic group for (a) parvalbumin (PV) mRNA and (b–d) somatostatin (SST) mRNA. Note the varying scales for the y axes between (a) and (b–d). Subjects with bipolar disorder (BPD) that had antipsychotic medication use at the time of death and their matched controls (Con) were removed and the subjects with BPD (n = 12) demonstrated a trending reduction in PV mRNA expression (a). Subjects with major depressive disorder (MDD) that were using benzodiazepines or sodium valproate at the time of death and their matched controls were removed and the subjects with MDD (n = 15) demonstrated a significant reduction of SST mRNA expression (b). Subjects with BPD (c) or MDD (d) that were using SSRIs at the time of death and their matched controls were removed and the subjects with MDD (n = 14) demonstrated a significant reduction of SST mRNA expression (d) while the subjects with BPD (n = 10) did not demonstrate a significant alteration in SST mRNA expression (c).